71 results
8-K
EX-99.1
HUMA
Humacyte Inc
22 Mar 24
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
7:06am
presentation titled “Phase 2/3 Study for the Evaluation of Safety and Efficacy of HAV for Vascular Reconstruction in Patients with Limb or Life-Threatening
8-K
EX-1.1
HUMA
Humacyte Inc
4 Mar 24
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
6:53am
) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies; and (vi) all other
8-K
EX-99.1
HUMA
Humacyte Inc
29 Feb 24
Other Events
4:02pm
Grafts No unexpected safety signals CLN-PRO-V005 Phase 2/ 3 Pivotal Trial Primary endpoint 30-day patency in patients with extremity injuries Single-arm … the first year Safety: interventions, infections, etc. Duration Subjects followed for 24 months after implantation Sites 30 centers in the U.S
8-K
EX-99.1
ivgan
12 Sep 23
Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma
7:09am
8-K
EX-99.1
yxh91v5kc8ak1t4tu506
14 Aug 23
Humacyte Second Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
kedmijfaow
12 May 23
Humacyte First Quarter 2023 Financial Results and Business Update
7:13am
8-K
EX-3.2
skwat65 9t377ospr7h
12 Dec 22
Amendments to Articles of Incorporation or Bylaws
4:04pm
424B3
o060 z4p16dt7b4owp
12 Aug 22
Prospectus supplement
9:11am
424B3
hh272 a8qgel39u6cj6j
13 May 22
Prospectus supplement
9:14am